Predicting How Radioactive Peptide Tracers Distribute in Neuroendocrine Cancer Patients

Researchers built a physiologically based pharmacokinetic (PBPK) model that accurately predicts how two gallium-68-labeled somatostatin peptides — DOTATATE and HA-DOTATATE — distribute through the body and into tumors of neuroendocrine cancer patients. Key findings: the uptake differences between the two peptides in organs were driven by their different receptor binding affinities, while tumor uptake was primarily determined by tumor blood flow and blood volume. The 'tumor sink effect' — where large tumors absorb so much peptide that normal organs get less — was only clinically relevant when total tumor volume exceeded about 550 mL, which affects a minority of patients.

The team developed a PBPK model incorporating receptor binding, internalization, recycling, renal clearance, and intracellular degradation. Three tumor compartments (primary, liver metastases, other metastases) were included. The model was validated against PET scan data from 98 GEP-NET patients and used for tumor sink simulations with increasing tumor volumes.

Gallium-68 DOTATATE PET scans are the gold standard for diagnosing and staging neuroendocrine tumors. This model helps clinicians understand why scan results vary between patients and between the two peptide tracers. Knowing that tumor sink only matters above 550 mL of tumor volume provides practical guidance for interpreting scans in patients with high tumor burden.

Peptide receptor radionuclide therapy (PRRT) with lutetium-177 DOTATATE (Lutathera) is a major advance in neuroendocrine tumor treatment. Understanding how the diagnostic version (gallium-68 DOTATATE) distributes through the body helps optimize both imaging and therapeutic dosing. This kind of pharmacokinetic modeling is increasingly important as personalized dosimetry becomes the standard in theranostics.

This is a modeling study — predictions are based on mathematical simulations validated against imaging data, not direct measurements of tissue peptide concentrations. The model assumptions about receptor density, binding kinetics, and tumor vascularity may not capture all patient-to-patient variability. The study focused specifically on gastroenteropancreatic NETs; applicability to other NET types is uncertain.